Funding of $3.5 million Secured for Pioneering Artificial Intelligence in Biotech Studies by ScienceMachine
In the rapidly evolving world of biotechnology and pharmaceuticals, a London-based startup, ScienceMachine, is making significant strides with its innovative AI solution. Launched in 2025, ScienceMachine's AI agent, Sam, functions as a 24/7 AI bioinformatician, fully automating the data analysis pipeline for biotech and pharmaceutical companies [1][2].
Sam, the real, production-grade autonomous AI agent, is designed to integrate directly with existing databases and lab workflows, processing experimental data to find patterns, insights, and potential breakthroughs without manual intervention [1]. This continuous automation addresses a major bottleneck in life sciences research, where teams face an overwhelming influx of complex biological data but lack sufficient data scientists or domain experts with AI training [1].
By automating internal workflows, Sam significantly accelerates scientific discovery, cutting costs and shortening R&D timelines for clients from months to hours [1][2]. The impact of Sam is evident, with early customers reporting achieving results a third of the time, at a fraction of the price, and of a higher quality than they could have achieved on their own [1].
Recently, ScienceMachine raised $3.5 million (or approximately €2.9 million) in a pre-seed funding round to support further product development and to expand its customer base from startups to larger biotech and pharma companies, where the demand and contract values are higher [1][2]. The funding round was led by Revent and Nucleus Capital, with participation from strategic angels [1].
The funding will support product development and hiring, particularly in sales and pharma partnerships. ScienceMachine plans to expand its reach from biotech startups into larger companies, where the need for scalable, flexible data automation is even greater [1].
Maximilian Schwarz, General Partner at Nucleus, expressed confidence that agent-based architectures are poised to become the leading interface for scientific software, positioning ScienceMachine ideally to dramatically expand access to complex bioinformatics for wet-lab scientists and speed up iteration cycles [1].
Rebecca Brill, Principal at Revent, described ScienceMachine as one of the most impressive examples of pure execution, perfectly positioned to disrupt one of the largest and most important markets in the world [1]. Lorenzo Sani, CEO and Co-founder of ScienceMachine, emphasizes that their goal is to help biopharma make groundbreaking discoveries more rapidly and affordably, with Sam positioned as a transformative tool in research and discovery over the coming years [2].
Maximilian Schwarz added that ScienceMachine is ideally positioned to dramatically expand access to complex bioinformatics for wet-lab scientists and speed up iteration cycles, making complex bioinformatics accessible to wet-lab scientists [1]. Sam handles everything, from data cleaning to exploratory analysis to visualization, continuously and autonomously unlocking faster research cycles and dramatically reducing the cost of discovery [1].
In conclusion, ScienceMachine's Sam represents a game-changing innovation in the field of biomedical research. By accelerating biotech data interpretation, democratizing access to complex bioinformatics, and expediting the scientific discovery process at scale, this autonomous AI agent has the potential to reshape how biomedical research teams handle data, enabling faster breakthroughs and improved R&D productivity across the biotech and pharmaceutical sectors [1][2].
- ScienceMachine's innovative AI solution, Sam, is revolutionizing the financial landscape of the biotech and pharmaceutical industry by providing affordable and efficient data analysis services, having recently secured $3.5 million in pre-seed funding.
- The integration of Sam's autonomous AI technology into health and wellness sectors, particularly medical-conditions research, could significantly improve health outcomes by accelerating scientific discovery and reducing R&D timelines.
- Likewise, the business opportunities for ScienceMachine extend beyond the biotech and pharmaceutical sectors, as its technology offers promise in the field of technology and investing, with potential for scalable, flexible data automation in various industries.
